Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regenxbio

7.85
-0.0500-0.63%
Post-market: 7.850.00000.00%19:48 EDT
Volume:637.52K
Turnover:5.01M
Market Cap:395.55M
PE:-2.53
High:8.12
Open:7.82
Low:7.72
Close:7.90
52wk High:13.48
52wk Low:5.04
Shares:50.39M
Float Shares:41.29M
Volume Ratio:1.03
T/O Rate:1.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0996
EPS(LYR):-4.5871
ROE:-62.49%
ROA:-17.88%
PB:1.85
PE(LYR):-1.71

Loading ...

Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Quoin Pharmaceuticals (QNRX) and RegenXBio (RGNX)

TIPRANKS
·
Aug 08

REGENXBIO Is Maintained at Overweight by Barclays

Dow Jones
·
Aug 08

RBC Cuts Price Target on REGENXBIO to $17 From $21, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Aug 08

REGENXBIO Reports Q2 2025 Financial Results and Progress

TIPRANKS
·
Aug 08

Raymond James Remains a Buy on RegenXBio (RGNX)

TIPRANKS
·
Aug 08

Regenxbio Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

BRIEF-Regenxbio Inc - Phase Iib/Iii Trial To Be Initiated For Diabetic Retinopathy

Reuters
·
Aug 07

Regenxbio Q2 EPS $(1.38) Misses $(1.10) Estimate, Sales $21.36M Miss $28.11M Estimate

Benzinga
·
Aug 07

Regenxbio Inc - Phase Iib/Iii Trial to Be Initiated for Diabetic Retinopathy

THOMSON REUTERS
·
Aug 07

Regenxbio Inc - to Receive $100 Mln Upon First Subject Dosed

THOMSON REUTERS
·
Aug 07

Regenxbio Inc expected to post a loss of $1.10 a share - Earnings Preview

Reuters
·
Aug 05

Regenxbio Inc expected to post a loss of $1.10 a share - Earnings Preview

Reuters
·
Jul 28

REGENXBIO Announces Promising Preclinical Results for RGX-202 Gene Therapy in Treating Duchenne Muscular Dystrophy, Highlighting Potential for Improved Patient Outcomes

Reuters
·
Jul 10

RBC Capital Remains a Buy on RegenXBio (RGNX)

TIPRANKS
·
Jul 08

RBC Cuts Price Target on REGENXBIO to $21 From $25, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jul 07

Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street. -- Barrons.com

Dow Jones
·
Jun 20

Gene Therapy Has Lost Support on Wall Street. There's Still Hope for Big Cures. -- Barrons.com

Dow Jones
·
Jun 19

BofA expects no changes for Regenxbio regimen after competitor safety issue

TIPRANKS
·
Jun 17

Regenxbio files to sell 268,096 shares of common stock for holders

TIPRANKS
·
Jun 14

REGENXBIO Is Maintained at Buy by Chardan Capital

Dow Jones
·
Jun 09